跳到正文
原文
Endpoints News 生物医药· Lei Lei Wu·· 2026-10-06精选AI 评分67

ArriVent肺癌药firmonertinib III期试验失败,公司股价大跌

ArriVent's lung cancer drug firmonertinib fails key late-stage trial, stock tanks

AI 导读

ArriVent BioPharma报告其主打肺癌药物firmonertinib在III期临床试验中失败,公司股价随之大跌。

推荐理由

III期失败直接冲击ArriVent核心管线估值,该结果对肺癌靶向药竞争格局、企业估值与投资判断均具有参考价值。

正文 · 原文

Ar­riVent Bio­Phar­ma, an ear­ly adopter of the Chi­na li­cens­ing mod­el, re­port­ed that its lead lung can­cer drug failed a Phase 3 tri­al.

Fir­mon­er­tinib, an EGFR …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news